Founded in 1951, SERB is a European pharmaceutical group specializing in the development, production and distribution of drugs for critical care, medical emergencies and rare diseases. Historically rooted in France, the company has undergone major international expansion since the 2000s, enabling it to become a global player in the field of specialized pharmaceutical treatments.
SERB stands out for its expertise in complex therapeutic areas that are poorly addressed by conventional medicine. Its portfolio includes pharmaceutical specialties used in clinical toxicology, neurology, endocrinology, intensive care medicine, gastroenterology and perinatology. With a presence in over 80 countries, including Europe, the Middle East, Australia, the United States and Japan, SERB offers essential therapeutic solutions to patients whose needs are often considered unmet.
SERB focuses its activities on therapeutic segments with high medical value, often neglected by the traditional pharmaceutical industry. These are mainly clinical areas where access to specific drugs can be critical, even vital.
The laboratory is recognized in particular for :
Antidotes for acute intoxication or drug overdoses
Its adjunctive treatments in NRBC (nuclear, radiological, biological, chemical) toxicology
Medicines for the prevention of congenital malformations,thyroid insufficiency, certain forms of anemia, and rare neurological conditions.
Its growing commitment to the field of intensive care, consolidated by the acquisition of BTG Specialty Pharmaceuticals in 2021, which has enabled SERB to reinforce its position as world leader in this field.
While SERB is recognized for its central role in specialized hospital circuits, the laboratory is also developing solutions that can be found in household medicine cabinets, in response to common pathologies such as digestive disorders or nutritional deficiencies.
Importal is indicated for the symptomatic treatment of constipation. Based on lactitol, it acts by increasing the water content of stools, facilitating their evacuation. It is available in three formulations for different ages: adults, children aged 7 and over, and infants from birth. Importal can also be used in the management ofhepatic encephalopathy, by reducing the absorption of intestinal toxins.
Rocgel is analuminum oxide-based medication indicated for heartburn, heartburn and gastro-oesophageal reflux. By neutralizing gastric acidity, it rapidly relieves epigastric pain and the sensation of acid reflux. This medicine should be taken at a distance from other oral treatments to avoid altering their absorption.
Spéciafoldine is afolic acid-based speciality, essential for the prevention of neural tube defects (NTDs) in women wishing to become pregnant. The 0.4 mg dosage is recommended for primary prevention in women of childbearing age, while the 5 mg dosage is reserved for patients at increased risk (family history of NTFA, anti-epileptic treatments, malnutrition, alcoholism, absorption disorders).
Toxicarb is a drinkable suspension of activated charcoal, used in emergency cases of intoxication or drug overdose. Thanks to its high adsorption capacity, charcoal binds toxins in the digestive tract, preventing them from entering the systemic circulation. It can be administered to people of all ages, including infants, in adjusted doses.
SERB is actively pursuing a global expansion strategy. After the acquisition of Veriton Pharma in 2020, strengthening its presence in neurology and rare diseases, the purchase of BTG Specialty Pharmaceuticals in 2021 marked a decisive strategic step. This operation enabled the Group to:
broaden its portfolio of critical care drugs
strengthen its global production and distribution capabilities
gain a direct foothold in the US market, consolidating its position as world leader in specialty care.
Thanks to a network of experienced distributors and a direct presence in several strategic regions, SERB ensures the availability of its medicines in over 80 countries, guaranteeing rapid access to essential treatments.
In addition to the clinical efficacy of its products, SERB makes it a point of honor to offer medicines at affordable prices, so that they remain accessible to the greatest possible number of patients, including those with chronic conditions or long treatment times. This ethical approach aims to limit cost-related treatment disruptions, particularly for patients suffering from rare diseases or pathologies requiring prolonged treatment.
The company also ensures compliance with European and international standards in terms of quality, traceability, pharmacovigilance and health safety.
The SERB laboratory stands out for its unique positioning: it places pharmaceutical technology at the service of patients facing complex, rare or urgent clinical situations. Whether for acute intoxications, digestive disorders, perinatal prevention or intensive support treatments, SERB develops targeted solutions based on science, safety and accessibility.
By expanding internationally and strengthening its portfolio through strategic acquisitions, SERB confirms its role as akey global player in the field of essential medicines for patients with specific therapeutic needs.
